# Pharmaceutical manufacturing investment trends

> Live situation record from CLSTR: https://clstr.news/situations/pharmaceutical-manufacturing-investment-trends
> Updated: 2026-08-15T23:47:00.000Z. Sources: 22. Developments: 4.

Pharmaceutical companies are making significant investments in manufacturing infrastructure, with a notable focus on expanding capacity within the United States. 

Eli Lilly and Resilience announced a $750 million partnership to expand U.S. pharmaceutical manufacturing, specifically targeting the production of medicines for diabetes and obesity in the Cincinnati, Ohio region. This move is intended to strengthen domestic supply chains amid potential U.S. policy shifts regarding tariffs on branded drugs.

Bristol Myers Squibb is also expanding its U.S. footprint with a $2.3 billion investment to build a 600,000-square-foot multi-modal manufacturing campus at Generation Park in Houston, Texas. The facility will utilize a modular design to produce biologics, small-molecule medicines, and antibody-drug conjugates, allowing for future reconfiguration to meet evolving scientific needs. The project is expected to create approximately 500 permanent skilled jobs and 2,000 construction-related positions between 2027 and 2030. This initiative aligns with the company’s broader $40 billion commitment to expand domestic manufacturing and research in the U.S.

While expanding in the U.S., Eli Lilly reported scaling back a planned $2.5 billion project in Alzey, Germany, by 50 percent. The company attributed this reduction to German healthcare austerity measures, which it criticized as a “savings law” that undermines the country’s competitiveness for pharmaceutical investment. Despite the reduced scope and impact on the original goal of 1,000 jobs, Eli Lilly intends to proceed with the facility's opening, which is scheduled for late 2027.

## Claims

- Eli Lilly criticized the German government's GKV contribution rate stabilization law, labeling it a 'savings law' rather than a healthcare reform. (corroborated by 2 sources)
- Eli Lilly will proceed with the opening of its pharmaceutical production facility in Alzey, Germany, despite reduced investment levels. (corroborated by 2 sources)
- The company has reduced the remaining scope of the Alzey project by 50 percent compared to original plans. (corroborated by 2 sources)
- The original investment plan for the Alzey facility was $2.5 billion (2.16 billion euros). (corroborated by 2 sources)
- The Alzey facility was originally intended to create up to 1,000 specialist jobs. (corroborated by 2 sources)
- The production facility in Alzey is scheduled to open by the end of 2027. (corroborated by 2 sources)

## Timeline

### 2026-08-15: Bristol Myers Squibb to invest $2.3B in Houston manufacturing campus

Bristol Myers Squibb will invest $2.3 billion in a modular manufacturing campus in Houston, Texas, creating nearly 500 jobs to produce various medicines and support its U.S. manufacturing commitment.

4 sources. https://clstr.news/cluster/bristol-myers-squibb-to-invest-23b-in-houston-manufacturing-campus

### 2026-08-13: Bristol Myers Squibb to invest $2.3 billion in Houston manufacturing campus

Bristol Myers Squibb will invest $2.3 billion in a new multi-modal manufacturing campus in Houston, Texas, creating hundreds of skilled jobs and supporting the production of next-generation medicines.

3 sources. https://clstr.news/cluster/bristol-myers-squibb-to-invest-23-billion-in-houston-manufacturing-campus

### 2026-08-10: Bristol Myers Squibb to invest $2.3bn in Houston biopharma campus

Bristol Myers Squibb is investing $2.3 billion in a new Houston manufacturing campus, while Eli Lilly scales back a $2.5 billion project in Germany due to healthcare policy changes.

15 sources. https://clstr.news/cluster/eli-lilly-proceeds-with-alzey-plant-despite-reduced-investment

### 2026-07-30: Eli Lilly partners with Resilience on $750 million US drug‑manufacturing expansion

Eli Lilly and Resilience will invest $750 million to expand US drug manufacturing, adding capacity, 400 high‑skill jobs in Cincinnati and including Lilly’s KwikPen device, part of Lilly’s $55 billion US rollout

9 sources. https://clstr.news/cluster/eli-lilly-partners-with-resilience-on-750-million-us-drugmanufacturing-expansion

---
Cite as: Pharmaceutical manufacturing investment trends. CLSTR, https://clstr.news/situations/pharmaceutical-manufacturing-investment-trends